Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The clinical implications of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Abs) are increasing. Establishing MOG-Ab assays is essential for effectively treating patients with MOG-Abs. We established an in-house cell-based assay (CBA) to detect MOG-Abs to identify correlations with patients’ clinical characteristics. Methods: We established the CBA using HEK 293 cells transiently overexpressing full-length human MOG, tested it against 166 samples from a multicenter registry of central nervous system (CNS) inflammatory disorders, and compared the results with those of the Oxford MOG-Ab-based CBA and a commercial MOG-Ab CBA kit. We recruited additional patients with MOG-Abs and compared the clinical characteristics of MOG-Ab-associated disease (MOGAD) with those of neuromyelitis optica spectrum disorder (NMOSD). Results: Of 166 samples tested, 10 tested positive for MOG-Abs, with optic neuritis (ON) being the most common manifestation (4/15, 26.7%). The in-house and Oxford MOG-Ab CBAs agreed for 164/166 (98.8%) samples (κ=0.883, P<0.001); two patients (2/166, 1.2%) were only positive in our in-house CBA, and the CBA scores of the two laboratories correlated well (r=0.663, P<0.001). The commercial MOG-Ab CBA kit showed one false-negative and three false-positive results. The clinical presentation at disease onset differed between MOGAD and NMOSD; ON was the most frequent manifestation in MOGAD, and transverse myelitis was most frequent in NMOSD. Conclusions: The in-house CBA for MOG-Abs demonstrated reliable results and can potentially be used to evaluate CNS inflammatory disorders. A comprehensive, long-term study with a large patient population would clarify the clinical significance of MOG-Abs.
Abstract
Background: The clinical implications of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Abs) are increasing. Establishing MOG-Ab assays is essential for effectively treating patients with MOG-Abs. We established an in-house cell-based assay (CBA) to detect MOG-Abs to identify correlations with patients’ clinical characteristics. Methods: We established the CBA using HEK 293 cells transiently overexpressing full-length human MOG, tested it against 166 samples from a multicenter registry of central nervous system (CNS) inflammatory disorders, and compared the results with those of the Oxford MOG-Ab-based CBA and a commercial MOG-Ab CBA kit. We recruited additional patients with MOG-Abs and compared the clinical characteristics of MOG-Ab-associated disease (MOGAD) with those of neuromyelitis optica spectrum disorder (NMOSD). Results: Of 166 samples tested, 10 tested positive for MOG-Abs, with optic neuritis (ON) being the most common manifestation (4/15, 26.7%). The in-house and Oxford MOG-Ab CBAs agreed for 164/166 (98.8%) samples (κ=0.883, P<0.001); two patients (2/166, 1.2%) were only positive in our in-house CBA, and the CBA scores of the two laboratories correlated well (r=0.663, P<0.001). The commercial MOG-Ab CBA kit showed one false-negative and three false-positive results. The clinical presentation at disease onset differed between MOGAD and NMOSD; ON was the most frequent manifestation in MOGAD, and transverse myelitis was most frequent in NMOSD. Conclusions: The in-house CBA for MOG-Abs demonstrated reliable results and can potentially be used to evaluate CNS inflammatory disorders. A comprehensive, long-term study with a large patient population would clarify the clinical significance of MOG-Abs.
참고문헌 (32)
- Prüss H, "Autoantibodies in neurological disease", Nat Rev Immunol, 21, pp.798~813 (2021)
- Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
- Jeyalatha MV, "An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders", J Clin Neurol, 18, pp.152~162 (2022)
- Jarius S, "MOG encephalomyelitis : international recommendations on diagnosis and antibody testing", J Neuroinflammation, 15, pp.134~ (2018)
- de Mol CL, "The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults", Mult Scler, 26, pp.806~814 (2020)
- Kim KH, "Clinical and radiological features of myelin oligodendrocyte glycoprotein-associated myelitis in adults", J Clin Neurol, 18, pp.280~289 (2022)
- Akaishi T, "Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder", Neurology, 97, pp.e1~e12 (2021)
- Sechi E, "Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies", Mult Scler, 27, pp.303~308 (2021)
- Cobo-Calvo A, "Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease", Ann Neurol, 89, pp.30~41 (2021)
- Hyun JW, "Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases", Mult Scler, 27, pp.964~967 (2021)
- Polman CH, "Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria", Ann Neurol, 69, pp.292~302 (2011)
- Thompson AJ, "Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria", Lancet Neurol, 17, pp.162~173 (2018)
- Waters P, "MOG cell-based assay detects non-MS patients with inflammatory neurologic disease", Neurol Neuroimmunol Neuroinflamm, 2, pp.e89~ (2015)
- Waters PJ, "A multicenter comparison of MOG-IgG cell-based assays", Neurology, 92, pp.e1250~5 (2019)
- Kang ES, "Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorder", Ann Lab Med, 32, pp.331~338 (2012)
- Fujihara K, "Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease : current topics", Curr Opin Neurol, 33, pp.300~308 (2020)
- Lee HJ, "Chronic relapsing inflammatory optic neuropathy(CRION) : a manifestation of myelin oligodendrocyte glycoprotein antibodies", J Neuroinflammation, 15, pp.302~ (2018)
- Hamid SHM, "What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients", J Neurol, 264, pp.2088~2094 (2017)
- Reindl M, "The spectrum of MOG autoantibody-associated demyelinating diseases", Nat Rev Neurol, 9, pp.455~461 (2013)
- Cao Y, "A case of MOGAD complicated with cerebral vasculitis : case report and literature review", J Clin Neurol, 19, pp.96~98 (2023)
- Jurynczyk M, "Clinical presentation and prognosis in MOG-antibody disease : a UK study", Brain, 140, pp.3128~3138 (2017)
- Kunchok A, "Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients", JAMA Neurol, 77, pp.257~259 (2020)
- Kim SM, "Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS", Neurol Neuroimmunol Neuroinflamm, 2, pp.e163~ (2015)
- Lee HL, "Results of a survey on diagnostic procedures and treatment choices for neuromyelitis optica spectrum disorder in Korea : beyond the context of current clinical guidelines", J Clin Neurol, 18, pp.207~213 (2022)
- Gastaldi M, "Cell-based assays for the detection of MOG antibodies : a comparative study", J Neurol, 267, pp.3555~3564 (2020)
- Reindl M, "International multicenter examination of MOG antibody assays", Neurol Neuroimmunol Neuroinflamm, 7, pp.e674~ (2020)
- Lui A, "High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics", Mult Scler Relat Disord, 56, pp.103253~ (2021)
- Cobo-Calvo A, "Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults", J Neurol, 266, pp.806~815 (2019)
- van Pelt ED, "Neuromyelitis optica spectrum disorders : comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands", Eur J Neurol, 23, pp.580~587 (2016)
- Hyun JW, "CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder : no evidence of astrocyte damage", J Neuroinflammation, 19, pp.86~ (2022)
- Sepúlveda M, "Neuromyelitis optica spectrum disorders : comparison according to the phenotype and serostatus", Neurol Neuroimmunol Neuroinflamm, 3, pp.e225~ (2016)
- Banwell B, "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease : International MOGAD Panel proposed criteria", Lancet Neurol, 22, pp.268~282 (2023)